Get the Stockscreener App
2.45
2.51%
0.06
Proqr Therapeutics N V stock is traded at $2.45, with a volume of 374.28K.
It is up +2.51% in the last 24 hours and up +15.84% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$2.39
Open:
$2.43
24h Volume:
374.28K
Relative Volume:
1.24
Market Cap:
$257.77M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-6.4678
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
+8.89%
1M Performance:
+15.84%
6M Performance:
+20.10%
1Y Performance:
+29.97%
1-Day Range:
$2.36
$2.50
1-Week Range:
$2.22
$2.50
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
2.45 | 251.77M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
Building trade automation scripts for ProQR Therapeutics N.V.2025 Bull vs Bear & Smart Money Movement Alerts - Newser
Can trapped investors hope for a rebound in ProQR Therapeutics N.V.2025 Volume Leaders & Community Verified Watchlist Alerts - Newser
What high frequency data says about ProQR Therapeutics N.V.2025 Historical Comparison & Entry Point Strategy Guides - Newser
How high can ProQR Therapeutics N.V. stock goJobs Report & Daily Momentum Trading Reports - Newser
Will ProQR Therapeutics N.V. price bounce be sustainableQuarterly Profit Summary & Weekly Watchlist of Top Performers - Newser
Custom strategy builders for tracking ProQR Therapeutics N.V.Trend Reversal & Free Reliable Trade Execution Plans - Newser
Can technical indicators confirm ProQR Therapeutics N.V.’s reversal2025 Price Targets & AI Enhanced Trading Signals - Newser
ProQR Therapeutics: Not A Needle Mover Just Yet - Seeking Alpha
What is ProQR Therapeutics N.V.’s book value per shareProfit Target & Safe Swing Trade Setup Alerts - خودرو بانک
Intraday pattern recognizer results for ProQR Therapeutics N.V.Analyst Downgrade & Smart Allocation Stock Tips - Newser
What are ProQR Therapeutics N.V.’s recent SEC filings showingJuly 2025 Decliners & Verified Entry Point Detection - خودرو بانک
What to expect from ProQR Therapeutics N.V. in the next 30 daysQuarterly Performance Summary & Community Trade Idea Sharing Platform - Newser
Can ProQR Therapeutics N.V. generate free cash flowProduct Launch & Free Expert Verified Stock Movement Alerts - خودرو بانک
Sentiment Recap: What is the target price for ProQR Therapeutics N.V. stockRate Cut & Stepwise Trade Signal Implementation - خودرو بانک
Is ProQR Therapeutics N.V. meeting your algorithmic filter criteriaPortfolio Return Report & Real-Time Stock Movement Alerts - Newser
Can ProQR Therapeutics N.V. be recession proofJuly 2025 Big Picture & Growth Focused Investment Plans - خودرو بانک
How hedge fund analytics apply to ProQR Therapeutics N.V. stockJuly 2025 Volume & Consistent Growth Equity Picks - Newser
Is ProQR Therapeutics N.V. likely to announce a buyback2025 Key Lessons & Growth Focused Stock Pick Reports - beatles.ru
Is ProQR Therapeutics N.V. stock ready for a breakoutJuly 2025 Highlights & Technical Entry and Exit Alerts - Newser
Real time breakdown of ProQR Therapeutics N.V. stock performancePortfolio Return Report & Weekly High Momentum Picks - Newser
Retinitis Pigmentosa Market to Evolve Rapidly Over the Next - openPR.com
Is ProQR Therapeutics N.V. undervalued by DCF analysisMarket Volume Report & Smart Investment Allocation Tips - خودرو بانک
Should you buy the dip on ProQR Therapeutics N.V.2025 Year in Review & Verified Momentum Stock Ideas - خودرو بانک
Candlestick signals on ProQR Therapeutics N.V. stock todayQuarterly Earnings Summary & Fast Exit and Entry Strategy Plans - Newser
Is ProQR Therapeutics N.V. a potential multi bagger2025 Macro Impact & Short-Term High Return Ideas - خودرو بانک
Momentum divergence signals in ProQR Therapeutics N.V. chartJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
Can ProQR Therapeutics N.V. hit a new high this monthJuly 2025 Fed Impact & Growth Focused Entry Point Reports - Newser
Chart based analysis of ProQR Therapeutics N.V. trendsLong Setup & Risk Controlled Swing Alerts - Newser
Will ProQR Therapeutics N.V. benefit from current market trendsJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - khodrobank.com
Pullback Watch: Can ProQR Therapeutics N.V. be recession proofWeekly Stock Recap & Accurate Entry and Exit Point Alerts - خودرو بانک
What Fibonacci levels say about ProQR Therapeutics N.V. reboundJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - Newser
Is it too late to sell ProQR Therapeutics N.V.2025 Trade Ideas & Fast Gain Stock Tips - Newser
ProQR Therapeutics N.V. stock trend outlook and recovery pathQuarterly Profit Review & Technical Pattern Based Signals - Newser
ProQR Therapeutics N.V. recovery potential after sell off2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - Newser
Can ProQR Therapeutics N.V. recover in the next quarterJuly 2025 Trends & Low Risk Growth Stock Ideas - Newser
Buy Signal: What are ProQR Therapeutics N.V.’s recent SEC filings showingM&A Rumor & Growth Focused Investment Plans - خودرو بانک
How cyclical is ProQR Therapeutics N.V.’s revenue streamGlobal Markets & Verified Entry Point Detection - خودرو بانک
Movement Recap: Can ProQR Therapeutics N.V. be recession proofJuly 2025 Update & High Accuracy Trade Signal Alerts - خودرو بانک
Is ProQR Therapeutics N.V. benefiting from innovation trendsAnalyst Downgrade & Precise Entry and Exit Recommendations - خودرو بانک
Can ProQR Therapeutics N.V. reach resistance levels soon2025 Market Outlook & Growth-Oriented Investment Plans - خودرو بانک
What is the earnings history of ProQR Therapeutics N.V.July 2025 Rallies & Daily Profit Focused Stock Screening - خودرو بانک
Research Analysts Issue Forecasts for PRQR FY2025 Earnings - MarketBeat
Is ProQR Therapeutics N.V. building a consolidation baseMarket Growth Report & Daily Market Momentum Tracking - Newser
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):